This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
AstraZeneca (AZN.L) - Is struggling with loss of patents on blockbusters like cholesterol pill Crestor as it reported another quarter of falling drug sales. It awaits pivotal clinical trial data that may revive its fortunes. Q1 revenue fell 12% to $5.4bn in line with forecasts, although earnings per share beat by rising 4% in dollar terms to 99c per share. Closing price 4686.00p (Reuters)
Lloyds (LLOY.L) – Saw strong underlying performance, a significant improvement in statutory profit up nearly 1% on expectations and returns with an increase in underlying profit of £2.1bn up 8% beating £1.94bn expected. There was also a 44% reduction in impairment charges. Closing price 67.41p (Bloomberg / Accendo Markets)
Persimmon Plc (PSN.L) – Saw 6% more visitors to development sites y-o-y, sales up 4% with total forward sales revenue, including legal completions taken to date in 2017 currently at £2.56bn, c.11% higher and average selling price up 4.1% to £229,500. Closing price 2286.00p (Reuters)
Travis Perkins (TPK.L) – Sees 2017 trading in line with expectations with total sales growing 4.9% in Q1, delivering solid like-for-like sales growth. Underlying trading in plumbing & heating continued to be tough with a decline in like-for-like sales of 1.1%. Closing price 1609.00p (Reuters)
For more information on any of these individual news items, call into the trading floor
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research